denocabtagene ciloleucel (CAR-T-19-DNR) / Immunotech Biopharm - LARVOL DELTA

VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN THE PHASE I CLINICAL TRIAL FOR THE DENOCABTAGENE CILOLEUCEL INJECTION (HKEXnews) - "The board...of directors...of the Company is pleased to announce that the Company has completed the first patient enrolment for its Phase I clinical trial for the Denocabtagene Ciloleucel Injection ('DCI') in the PRC on 7 November 2023, which marked the milestone of the Group’s development in its product pipeline. DCI, originally known as RC19D2, CAR-T-19-D2 and CAR-T-19-DNR, targets CD19 antigens and an antagonist of proteins in the downstream signaling of TGF-ß, it is an injection for the treatment of patients with relapsed and refractory diffuse large B-cell lymphoma ('DLBCL')....Based on the progress of clinical trial for DCI, it is expected that the target patient enrolment will complete in the year end of 2024 and the preliminary analysis and results will be published in the first half of 2025."

Enrollment status • P1 data • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P1 | N=25 | Recruiting | Sponsor: Beijing Yongtai Ruike Biotechnology Company Ltd

New P1 trial • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • MYC